Business
Cytokinetics Announces Additional Results from GALACTIC-HF Presented at American Heart Association Scientific Sessions 2021
Analysis from GALACTIC-HF Shows Treatment with Omecamtiv MecarbilAssociated with Significant Reduction in the Risk of Stroke Data on Analog to CK-3828136 Adds
About this update from Cytokinetics, Incorporated
[{"type":"text","content":"Analysis from GALACTIC-HF Shows Treatment with Omecamtiv MecarbilAssociated with Significant Reduction in the Risk of Stroke Data on Analog to CK-3828136 Adds Preclinical Support for Cardiac Troponin Activation as Novel Mechanism to Increase Cardiac Function without Impacting Cardiac Efficiency SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase 3 clinical trial evaluating omecamtiv mecarbil in patients with heart failure with reduced ejection fraction (HFrEF), were presented by Dr. John Teerlink, M.D., Professor of Medicine, University of California San Francisco, Director of Heart Failure, San Francisco Veterans Affairs Medical Center and Executive Committee Chair, GALACTIC-HF, at the American Heart Association (AHA) Scientific Sessions 2021. In addition, preclinical data were presented at the AHA Scientific Sessions by Ivan Luptak, M.D., Ph.D., Assistant Professor of Medicine, Boston University School of Medicine, on a closely related analog to CK-3828136 (CK-136), the company’s novel, selective cardiac troponin activator which is in development for the potential treatment of diseases associated with impaired cardiac contractility, such as HFrEF, right ventricular heart failure, and others. “The results from this post-hoc analysis from GALACTIC-HF showed that treatment with omecamtiv mecarbil significantly reduced the risk of stroke, a common comorbidity in patients with HFrEF, in addition to its previously demonstrated effect having met its primary composite endpoint of time to first heart failure event or cardiovascular death. Reducing stroke may be an important additional benefit to treatment with omecamtiv mecarbil in patients with HFrEF, many of whom are at high risk of having a stroke or have a history of stroke,” said Fady I. Malik, M.D., Ph.D., Cytokinetics’ Executive Vice President of Research & Development. “Additionally, the new data presented at AHA on a closely related analog to the cardiac troponin activator, CK-136, adds preclinical evidence that directly targeting the sarcomere through this novel mechanism may increase cardiac contractility without a negative impact on calcium cycling, dia...